Trials / Recruiting
RecruitingNCT05897320
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Eptinezumab in Paediatric Patients (6 to 17 Years) for the Preventive Treatment of Episodic Migraine
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 315 (estimated)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eptinezumab | Solution for infusion |
| DRUG | Placebo | Solution for infusion |
Timeline
- Start date
- 2023-06-08
- Primary completion
- 2027-07-06
- Completion
- 2027-08-31
- First posted
- 2023-06-09
- Last updated
- 2026-03-12
Locations
65 sites across 11 countries: United States, Argentina, Canada, Italy, Mexico, Poland, Portugal, Serbia, Spain, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05897320. Inclusion in this directory is not an endorsement.